The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Legend Biotech. These supporters have no influence over the production of the content.
Welcome to CAR-T & Cellular Therapy Focus
Explore the latest updates in this field by haematological disease and therapy type, showcasing expert interviews and discussions, podcasts and e-learning.
CAR-T and other cellular therapies are at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.